

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions and listings of claims in the application.

1-12. (canceled)

13. (withdrawn) A synthetic hTRT peptide restricted by a Class I major histocompatibility complex (MHC) molecule.

14. (withdrawn) A method for inducing and enhancing a CTL response against cancer cells, comprising: harvesting mammalian blood leucocytes; pulsing with an effective amount of hTRT; and contacting cancer cells with an effective amount of pulsed leucocytes.

15. (withdrawn) The method according to claim 13, wherein the contacting is accomplished *in vitro*.

16. (withdrawn) The method according to claim 13, wherein the contacting is accomplished *in vivo*.

17. (withdrawn) A method for targeting cytotoxic lymphocytes (CTL) to tumor cells by administering an effective amount of telomerase transcriptase (TRT) peptide to a mammalian recipient, which amount is effective to attract CTL to the tumor cells.

18. (withdrawn) The method according to claim 16, wherein the recipient is a cancer patient.

19. (previously presented) A composition for induction of a cytotoxic T lymphocyte response, comprising: at least one ~~HLA-A2-restricted~~ HLA-A2.1-restricted, human telomerase reverse transcriptase (TRT) peptide ~~in an amount effective for initiating and enhancing a cytotoxic T lymphocyte (CTL) response against an HLA-A2 positive target cell;~~ from seven to fifteen amino acid residues in length, and a physiologically acceptable carrier.

20. (canceled)

21. (currently amended) The composition of claim 19, wherein said at least one TRT peptide ~~comprises~~ consists of a peptide with a sequence set forth as SEQ ID NO:1.

22. (currently amended) The composition of claim 19, wherein said at least one TRT peptide ~~comprises~~ consists of a peptide with a sequence set forth as SEQ ID NO:2.

23. (canceled)

24. (currently amended) The composition of Claim 19, further comprising a helper peptide consisting of a peptide with a sequence set forth as SEQ ID NO:4.

25. (new) The composition of Claim 24, wherein said helper peptide is not conjugated to said TRT peptide.

26. (new) A composition comprising: at least one human telomerase reverse transcriptase (TRT) peptide from seven to fifteen amino acid residues in length, wherein said TRT peptide comprises a modification to enhance binding to HLA-A2.1.

27. (new) The composition of claim 26, further comprising a helper peptide consisting of a peptide with a sequence set forth as SEQ ID NO:4.

28. (new) The composition of Claim 26, wherein said modification is a tyrosine substitution.

29. (new) The composition of Claim 28, wherein said tyrosine substitution is at position 1 of a canonical HLA-A2.1 motif.

30. (new) The composition of Claim 28, wherein said TRT peptide is SEQ ID NO:18.

31. (new) The composition of Claim 28, wherein said TRT peptide is SEQ ID NO:20.
32. (new) The composition of Claim 28, wherein said TRT peptide is SEQ ID NO:22.
33. (new) The composition of Claim 28, further comprising an adjuvant.
34. (new) The composition of Claim 28, further comprising a physiologically acceptable carrier.
35. (new) The composition of Claim 34, wherein said carrier is a mammalian cell.